Summit Therapeutics Advances Ivonescimab Trials with Key Milestones and FDA Filing — Summit Therapeutics Inc.

Event summary

Summit Therapeutics reported $713.4 million in cash and short-term investments as of December 31, 2025, up from $412.3 million a year earlier.
The company's Biologics License Application (BLA) for ivonescimab in combination with chemotherapy was accepted by the FDA with a PDUFA goal action date of November 14, 2026.
Summit announced the activation of clinical trial sites for the Phase III ILLUMINE study evaluating ivonescimab in head and neck squamous cell carcinoma (HNSCC).
Non-GAAP operating expenses increased to $362.0 million for 2025, up from $175.0 million in 2024, driven by clinical trial expansions.

The big picture

Summit Therapeutics is aggressively expanding the clinical development of ivonescimab, a potentially first-in-class bispecific antibody targeting PD-1 and VEGF. The company's strategic focus on multiple cancer indications and global trials positions it to compete in the crowded immuno-oncology space, but success hinges on regulatory approvals and sustained financial resources.

What we're watching

Regulatory Timeline: The pace at which the FDA reviews Summit's BLA for ivonescimab will determine its commercialization timeline in the U.S.
Clinical Trial Progress: Whether Summit can maintain enrollment and data maturity across its multiple Phase III trials, particularly HARMONi-3 and ILLUMINE.
Financial Runway: How long Summit's current cash position will sustain its aggressive clinical development program without additional funding.